Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jad Chahoud"'
Autor:
Guillermo Garcia-Manero, Jad Chahoud, Naveen Pemmaraju, Jenny Dahl, Alessandra Ferrajoli, Jovitta Jacob, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Rebecca Garris, Naval Daver, Maria Khouri, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia
Publikováno v:
Blood. 126:1298-1298
Background: Patients with relapsed/refractory (R/R) ALL have limited therapeutical options. Monoclonal antibodies have shown to be effective. Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to calicheamicin that has shown
Autor:
Guillermo Garcia-Manero, Rebecca Garris, Jad Chahoud, Tapan M. Kadia, Jane Autry, Gautam Borthakur, Farhad Ravandi, Musa Yilmaz, Elias Jabbour, Koji Sasaki, Hagop M. Kantarjian, Jenny Dahl, Jorge E. Cortes, Alessandra Ferrajoli
Publikováno v:
Blood. 126:1335-1335
Introduction: Blinatumomab is a first-in-class Bispecific T-cell engaging (BiTE) antibody targeting CD19-positive malignant cells and CD3-positive T cells. It has shown activity in both R/R B-cell ALL and with persistent minimal residual disease (MRD
Autor:
Elias Jabbour, Koji Sasaki, Jad Chahoud, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Mark Brandt
Publikováno v:
Blood. 126:1369-1369
Background: Karyotype classification is one of the strongest independent prognostic indicators in AML. The majority of recurring chromosomal aberrations are associated with an individual prognosis, other less frequent like the Del (20q), have been mi
Autor:
Evguenia Gachimova, Jad Chahoud, Koji Sasaki, Musa Yilmaz, Maria Khouri, Rebecca Garris, Deborah A. Thomas, Elias Jabbour, Gautam Borthakur, Naveen Pemmaraju, Hagop M. Kantarjian, Susan O'Brien, Courtney D. DiNardo, Jorge E. Cortes, Farhad Ravandi, Guillermo Garcia-Manero
Publikováno v:
Blood. 126:3720-3720
Background: Liposomal vincristine has been approved as salvage chemotherapy for patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Replacement of regular vincristine with liposomal vincristine might lead to improve outcome with red
Autor:
Srdan Verstovsek, Marina Konopleva, Zeev Estrov, Koichi Takahashi, Jad Chahoud, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortes, Sherry Pierce, Musa Yilmaz, Guillermo Garcia-Manero, William G. Wierda, Nitin Jain, Koji Sasaki
Publikováno v:
Blood. 126:3722-3722
Introduction: Older age, poor performance status, diminished organ function and adverse genetic features are poor prognostic factors in treatment of ALL. Our goal is to develop prognostic models predicting complete response (CR), death in CR, 2-month
Autor:
Sherry Pierce, Naval Daver, Susan O'Brien, Guillermo Garcia-Manero, Paul Koller, Koji Sasaki, Farhad Ravandi, Naveen Pemmaraju, Jad Chahoud, Gautam Borthakur, Elias Jabbour, Tapan M. Kadia, Hagop M. Kantarjian, Jorge E. Cortes, Allison Pike, Mark Brandt
Publikováno v:
Blood. 126:2508-2508
Background: The combination of 7+3 with a purine nucleoside analogue improved overall survival (OS) in patients with acute myeloid leukemia (AML). We randomized patients to receive either clofarabine (CIA) or fludarabine (FIA) combined with idarubici
Autor:
Susan O'Brien, Deborah A. Thomas, Koji Sasaki, Guillermo Garcia-Manero, Musa Yilmaz, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Naveen Pemmaraju, Jorge E. Cortes, Rebecca Garris, Farhad Ravandi, William G. Wierda, Jad Chahoud, Haim G. Moore, Twilla Victoria Jeanis, Elias Jabbour, Alessandra Ferrajoli
Publikováno v:
Blood. 126:2496-2496
Background: Addition of tyrosine kinase inhibitors (TKIs) to chemotherapy improves outcome in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib is a more potent BCR-ABL inhibitor, and covers the T315I clones. The co
Autor:
Heather M Schroeder, Guillermo Garcia-Manero, Marina Konopleva, Jad Chahoud, Paul Koller, Naval Daver, Farhad Ravandi, Elias Jabbour, Koji Sasaki, Rebecca Garris, Maria Khouri, Srdan Verstovsek, Nitin Jain, Deborah A. Thomas, Hagop M. Kantarjian, Jorge E. Cortes, Susan O'Brien, Tapan M. Kadia
Publikováno v:
Blood. 126:1295-1295
Background: The hyper-CVAD regimen is an effective frontline regimen for de novo adult ALL. Expression of CD20 was identified as an adverse prognostic factor, associated with a higher incidence of relapse, lower 3-year complete remission duration (CR